Gyre Therapeutics Inc
GYRE
查看详细走势图
7.260USD
+0.070+0.97%
收盘 12/26, 16:00（美东）报价延迟15分钟
659.86M总市值
97.53市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.97%
5天
+1.82%
1月
-7.52%
6月
-2.16%
今年开始到现在
-40.00%
1年
-41.69%
查看详细走势图
TradingKey Gyre Therapeutics Inc股票评分
单位: USD 更新时间: 2025-12-26操作建议
Gyre Therapeutics Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名94/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价18.00。中期看，股价处于平稳状态。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Gyre Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
买入
评级
18.000
目标均价
+120.59%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Gyre Therapeutics Inc亮点
亮点风险
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
业绩高增长
公司营业收入稳步增长，连续3年增长13219.52%
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值97.53，处于3年历史高位
机构加仓
最新机构持股3.38M股，环比增加7.55%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值1.28K
Gyre Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Gyre Therapeutics Inc简介
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
公司代码GYRE
公司Gyre Therapeutics Inc
CEOZhang (Ping)
网址https://www.gyretx.com/
常见问题
Gyre Therapeutics Inc(GYRE)的当前股价是多少？
Gyre Therapeutics Inc(GYRE)的当前股价是 7.260。
Gyre Therapeutics Inc的股票代码是什么？
Gyre Therapeutics Inc的股票代码是GYRE。
Gyre Therapeutics Inc股票的52周最高点是多少？
Gyre Therapeutics Inc股票的52周最高点是14.423。
Gyre Therapeutics Inc股票的52周最低点是多少？
Gyre Therapeutics Inc股票的52周最低点是6.110。
Gyre Therapeutics Inc的市值是多少？
Gyre Therapeutics Inc的市值是659.86M。
Gyre Therapeutics Inc的净利润是多少？
Gyre Therapeutics Inc的净利润为12.09M。
现在Gyre Therapeutics Inc(GYRE)的股票是买入、持有还是卖出？
根据分析师评级，Gyre Therapeutics Inc(GYRE)的总体评级为买入，目标价格为18.000。
Gyre Therapeutics Inc(GYRE)股票的每股收益（EPS TTM）是多少
Gyre Therapeutics Inc(GYRE)股票的每股收益（EPS TTM）是0.074。
相关品种
